paano mag withdraw sa haha777

paano mag withdraw sa haha777 Microsoft unveils zero-water data centres to reduce AI climate impactFrom a plush armchair in his well-appointed study, Pat Carty chooses the tomes that caressed his cerebrum over the last year. ‘Comic books, the Bible, road maps, pornography, anything you wanna read, go out and sit in a field sometime,’ the great Paul Westerberg once sagely advised. With that in mind, here’s some of 2024’s best reading material, presented in no particular order but all worthy of your time and attention. (Canongate) It’s a bold claim because he’s so bloody good, but this old-school western and a poetic, lovers-on-the-run yarn may be Barry’s greatest achievement. Inspired by Cork miners moving to Butte, Montana in the late 1800s and a childhood love of cowboys, and influenced by Terence Malick and Cormac McCarthy, although the equal of both, every line here would be the pinnacle of a thousand lesser writers’ careers. The love story is touching and tragic and gets a suitable ending, the supporting cast are all mad as the wind, and the writer’s alter-ego is a hopeless rake. Brilliant. (New Island) Pirates are cool and O’Connor’s fictionalised retelling of the life of Anne Bonny reminds us of that certainty by having Bonny stand as a symbol for individuality, gender fluidity, and sexual liberation, a hero as relevant to our times as her own. There’s also the requisite amount of rogering, of both the Jolly and venereal kind, cads like Calico Jack, and general lawlessness to keep you going. It’s really a book about freedom. The fact that one of the pirates, a doubtless charming and handsome rogue, is called Patrick Carty did not in any way influence this book’s inclusion. (Jonathan Cape) Delivering on the promise his short stories showed, especially culchie/cop caper A Shooting In Rathreedane, Barrett stays in Mayo for this Booker Prize longlisted drug hawking drama. The Ferdia brothers kidnap Doll because his brother Cillian owes their boss Mulrooney for a cocaine consignment gone arseways. Hardly the most original plot under the sun but it’s the way, to paraphrase Frank Carson, Barrett tells it. The uniformity of small town living is perfectly captured and the cast, from Vinnie who sleeps under cars to the goat man to Sergeant Martin who one kidnapped a teacher to take her looking for UFOs, are as odd as two left feet. (Penguin) Banishing forever the awful memory of Colin Farrell in Alexander, Lennon shows that ancient Greeks with Dublin accents can actually be a good idea. Athenian prisoners are rotting in the stone quarries near the Sicilian city of Syracuse after they took a hammering during the Peloponnesian war. A couple of potters who sound like they’re from Crumlin, Lampo and Gelon, decide to stage Euripides plays using the prisoners as cast. Both funny and sad, Lennon’s accomplished and original debut is also a celebration of the transformative power of art, right up to the moving epilogue. (Doubleday) Carson is an author with more strings to her bow than three fiddlers. As great as her novels are, she’s equally adept at shorter fiction and each example collected here deserves some class of award. Whether it’s the dead smoker in the back of Grandma’s Sierra, Catholics speaking a slippery tingly, second language, a farmer praying for his cow, Malcolm trying to empty the sea of jellyfish, or the red hand of ulster in the fridge that won’t go away, the extraordinary crashes into the ordinary in extraordinary ways throughout. Magic realism? Magic writing. Hide Away – Dermot Bolger, Girl In The Making – Anna Fitzgerald, Hagstone – Sinéad Gleeson, Long Island – Colm Tóibín, Intermezzo – Sally Rooney, Heart, Be At Peace – Donal Ryan, Mouthing – Orla Mackey, The Women Behind The Door – Roddy Doyle, The Instruments Of Darkness – John Connolly, The Drowned – John Banville, The Coast Road – Alan Murrin, Witness 8 – Steve Cavanagh, The Hunter – Tana French (Hot Press Books) A Hot Press columnist from 1983 to 1993 when he became Ireland’s first Minister for the Arts, Culture and the Gaeltacht, Michael D. this year reviewed the hundreds of pieces he wrote and selected the ones that he feels still strongly resonate today. From parish pump politics and the rantings of Bishop Jeremiah Newman to strange Dáil machinations and his travels to El Salvador, Somalia and Chile, it’s a captivating read with the future President’s finely calibrated bullshit detector helping him get to the truth of the matter. With Hot Press editor, Niall Stokes, supplying contemporaneous introductions to these classic columns, you won’t find a better Christmas stocking-filler – even if we do say so ourselves! (The Bodley Head) Okay, Philipps isn’t actually Irish, but his book about a great and slightly unsung hero who, according to President Higgins, contributed ‘not only to Irish freedom but to the universal struggle for justice and human dignity’ more than warrants its place on this list. Philipps details Casement’s ‘three destinies’ – almost single-handedly, as Foreign Office consul in The Congo, taking down King Leopold II for human rights violations, uncovering more abuse in the South American rubber industry, and his part in the fight for Irish freedom which lead to his death sentence – in this gripping biography. Likeable smart arse, and as an economist the right man for the job, takes on the mammoth (and mammon) task of presenting a history of cash that stretches from 18,000 BC – where money was, perhaps unsurprisingly, “the first thing we wrote about” – to the current era. If it sounds like a dry subject for a book then fear not for McWilliams, a born talker, peppers his treatise with anecdotes like the influence of economic theory on Darwin and Hitler’s plans to derail the Brits through counterfeiting. I lasted half an hour in undergraduate economics, I might have hung on if I’d had this in my satchel. (Allen Lane) Irish history has its share of dark corners but there is no blacker spot on our collective past than the mother and baby homes. Hearing about hundreds of bodies in a septic tank in Tuam is one, horrific, thing but reading a book which makes it feel very personal is another matter entirely. Wills’ uncle gets a local girl pregnant in 1950s rural Cork and her cousin Mary is born in the Bessborogh Sacred Heart Home. Mary goes on to also become pregnant out of wedlock and ends her own life. Wills documents a ‘culture of silence’ that stained everyone it touched. (Gill Books) Rooney has been contributing his unique scraperboard (pencil drawings completed by scalpel) artwork to Hot Press since I was a very small boy. This book stemmed from work commissioned for The Story Of Ireland BBC documentary series, where he felt a particular and personal affinity for our ancestors who lived and died during the famine. His pieces are intensely moving, especially those depicting starving villagers, the workhouse, famine ships, and a striking work called ‘Death Stalks The Land’ in particular. (Head Of Zeus) I reckon Jordan is a better writer than a filmmaker, but he’s pretty hand at both disciplines and this poetic memoir handily combines them. Covering the background he came from to get where he is, his start in the movie industry assisting John Boorman with the Excalibur script in 1981 which helped him break into directing when Film On 4 took interest in Angel, and then onto success with The Crying Game, Interview With The Vampire, and Michael Collins, the star names like Liam Neeson, Julia Roberts, Tom Cruise, Cillian Murphy, and even Sinéad O’Connor come thick and fast. Who Killed Una Lynskey? – Mick Clifford, Murder At Lordship: Inside The Hunt For A Detective’s Killer – Pat Marry & Robin Schiller, Atlas of the Irish Civil War: New Perspectives – edited by Héléne O’Keeffe et al, A Season of Sundays – Sportsfile (Viking) A beautiful, sweeping epic that sways and flows like the mighty rivers within it, Shafak’s masterful novel has one drop of water at its centre which falls on to the head of King Ashurbanipal in the ancient city of Nineveh, then as snow on to the tongue of a baby born by the Thames in 1840 who grows up to uncover part of The Epic Of Gilgamesh, and then on to the present day. A brief overview can’t do justice to a novel that addresses global and sexual inequality and who holds dominion over history and how we are all joined to it. (Hutchinson Heinemann) Having already covered trees in his Pulitzer Prize-winning 2018 novel The Overstory, Powers turns his attention to the oceans, specifically the Pacific, which covers around 32 percent of the planet’s surface, more than all its landmass combined. The work of oceanographer Evie Beaulieu inspires Todd Keane who gets caught up in the ‘third industrial revolution’ of computing and creates an artificial intelligence. His school friend Rafi Young, a literature devotee, marries Ina Aroita, moving back to her island home of Makatea where all the strands of this ecological call to arms/plea for a less human-centric approach to tomorrow come together. (Viking) Boyd, an exceptional writer who gave us 2022’s fabulous The Romantic, maintains that writing 2014 James Bond caper Solo was ‘tremendous fun’ so why wouldn’t he want to create a secret agent of his own? Rather than ape Ian Fleming’s man, he goes in another direction. Gabriel Dax is a mediocre travel writer, who gets dumped by women, can’t hold his booze, isn’t much cop with firearms, and – Bond would balk – uses a second hand bicycle at one point. He is, despite all that, extremely likable and rumour has it Boyd plans to bring him back again in the future. Good. (Michael Joseph) The sickeningly handsome Pierce Brosnan, the most un-Navan Navan man of all time, came to fame through Remington Steel, a TV detective show where an eminently qualified woman hired a chancer to take her place in order to be taken seriously in a man’s world. That was in the 1980s but imagine how much worse it was in the 1580s where Picoult imagines Emilia Bassano, possibly the Dark Lady of the sonnets, as the actual author of the bard’s plays, who procures a hack actor by the name of Will Shakespeare as her Remington. Clever and pointed storytelling. (Hamish Hamilton) The third in her Trojan War series, The Voyage continues Barker’s remarkable retelling of ancient history/myth from the point of view of the women caught up in it. This entry covers the return to Mycenae by the victorious Agamemnon after the fall of Troy, haunted by the sacrifice of his daughter Iphigenia who he dispatched ten years before to please the gods. Naturally, Queen Clytemnestra is equally unhappy and out for revenge. She represents the past coming to claim its due from cruel, insecure, and superstitious men in the same way the priestess Cassandra stands in for all the unheard women of the ancient world. Odyssey – Stephen Fry, Table For Two – Amor Towles, You Like It Darker – Stephen King, The Ministry Of Time – Kaliane Bradley, James – Percival Everett, Godwin – Joseph O’Neill, Precipice– Robert Harris, Blood Ties – Jo Nesbo, Proof Of Innocence – Jonathan Coe, Karla’s Choice – Nick Harkaway (William Collins) Nobody does war like Hastings and Operation Biting is the book equivalent of a bank holiday movie. A brilliant chap in the air ministry notices mentions of the ancient goddess Freya, who could see for miles thanks to a stolen necklace, in German signals intercepted by the boffins at Bletchley Park. A raid is proposed to the Combined Operations HQ led by the vainglorious Lord Mountbatten. There’s also a “fantastically indiscrete” French spy, a horny novelist, and all manner of stiff upper lip types in a caper that should have gone sideways but managed to pull off a badly needed propaganda coup. (Torva) Terrifying step-by-step examination of the nightmare scenario where North Korea launch a nuclear attack on the United States. Thousands of years of groping towards civilisation are reversed in a mere seventy-two minutes. Rule 42 of the Geneva Convention is violated as the Koreans target a nuclear power plant, prompting the US to respond by levelling Pyongyang. However, the missiles have to overfly Russia, which drags them into the conflict along with the Chinese, who border Korea, and it’s game over for everyone. The matter-of-factness of Jacobsen’s account is chilling. (Viking) For those of a certain age, the Challenger Space Shuttle disaster is as ingrained in the memory as the JFK shooting or 9/11 is for others because we watched it happen on television. Higginbotham puts the work in, interviewing all involved and leaves you aghast at the risks NASA took throughout its history to maintain the forward motion needed to guarantee continued funding. Their Space Flight Participation Programme added teacher Christa McAuliffe to the crew, the reason why so many school children were watching when it all went wrong in January, 1986. The subsequent investigative hearings, starring Richard Feynman, are equally fascinating. (Allen Lane) ‘Why would anyone of sound mind send troops into a nuclear disaster zone?’ This question is at the heart of this scarcely believable account of the 35-day occupation of the infamous Chernobyl plant that followed Putin ordering the troops in after claiming Ukrainians were planning to produce WMDs. US intelligence had presumed that Russian forces would bypass the exclusion zone on their way towards Kyiv because what sane person wouldn’t? Heroes like foreman Valentyn Heiko emerge and a counteroffensive takes Chernobyl back, although Russia still controls Europe’s largest nuclear plant at Zaporizhzhia which is good news for nobody. (Profile Books) Let’s be honest, the art world, and the vast sums of money thrown about within it, is patently ridiculous. Don’t get me wrong, I can be as moved as the next fella by a well-placed daub but a book like this – Whitfield meets Inigo Philbrick as a student, they go into the art business, Philbrick thrives only to be arrested later on for one of the biggest art frauds ever (in the neighbourhood of $86 million) – will leave you convinced it’s all a massive cod. The author’s recounting of his mate’s moral-free machinations is guaranteed to have you picking your jaw up off the floor. The Siege – Ben Macintyre, Knife – Salman Rushdie, Autocracy, Inc – Anne Applebaum, Nexus – Yuval Noah Harari, A Voyage Around The Queen – Craig Brown, Sonny Boy – Al Pacino, A History Of The World In 12 Shipwrecks – David Gibbins (Faber) Celebrated producer Boyd (Nick Drake, R.E.M.) wrote a fine memoir back in 2006 (White Bicycles) but this gargantuan exploration of where the music came from is on another level altogether. Bursting with anecdote and big names like Paul Simon in Africa, George Harrison going Indian and Ry Cooder heading to Cuba, each chapter is really a book on its own, especially his exploration of the Jamaican sound from its birth out of American R&B to its influence on hip-hop. His take on technology in modern recording will separate the (old) men from the boys but this is required reading. (PVA Books) While lists are all well and good, the best music writing is about feel and how, like an aural equivalent of Proust’s biscuit, it takes you back where you once were. These essays cover everyone from Shostakovich to Dylan because everything ever recorded can hit someone in the right way and provide ‘a personal soundtrack to particular experiences’. Like all such compendiums you’ll nod in agreement – Aingeala Flannery on The Smiths and dodgy hairdos, Brian Dillion on Iggy Pop – and howl in anger – Wendy Erskine’s heretical disparagement of Rod Stewart – but that’s half the sport. (Nine Eight Books) As evidenced by the announcement only last month of a forthcoming Apple access (and excess) all areas documentary about the band, interest has yet to flag for the Fleetwood Mac story, perhaps the greatest soap opera in rock history. Blake captures it all, from Peter Green’s (‘the greatest guitarist of his generation, and then he wasn’t’) blues boomers to the wild success of Rumours, which definitely did not result in cocaine being blown up someone’s jacksie, and beyond. Everyone from Status Quo to Harry Styles chips in to a tale that never tires. (Bantam) ‘Why don’t old rockers retire?’ cub reporters often ask me in the halls of HP HQ, although I fear their ire aims at superannuated codgers like Stuart Clark and myself rather than Jagger et al. Hepworth, a commentator always worthy of attention, answers such queries with a why the hell would they? Using Live Aid as his starting point, where the old guard were reborn, he shows why McCartney, Springsteen, and even the relatively sprightly Bono became rock’s aristocracy and are still packing them out at a stadium near you. Old is not as old as it used to be. (Harper Collins) A half-formed rumour about Mitchell scribbled on an alley wall would be worth reading, not to mind this extensive biography, although Powers argues she isn’t a biographer at all, which covers everything Mitchell related, from the polio partly responsible for her unique guitar playing, to her time in Laurel Canyon, where talented men around her were left in the ha-penny place by her otherworldly creativity. Powers doesn’t shy away from ‘missteps’ like Joni’s blackface on the cover of Don Juan’s Reckless Daughter and is also, admirably, unsure about her recent resurgence. The book a genius deserves. Kate Bush’s Hounds Of Love – Leah Kardos, The Blues Brothers – Daniel De Visé, Street-Level Superstar: A Year With Lawrence – Will Hodgkinson, The Secret Public – Jon Savage, Uncommon People – Miranda Sawyer, Pressure Drop: Reggae In The Seventies – John MasouriaWill 2025 shine bright for ASX gold shares?

HUMA Lead Plaintiff Deadline Approaching – Contact Robbins LLP For Information About The Class Action Against Humacyte, Inc.

Investors swoop in to save German flying taxi startupA R Rahman, who recently announced his divorce from Saira Banu, has addressed the wave of rumours and false narratives circulating on social media. The couple, who were married for 29 years, parted ways amicably and requested privacy during this transition. However, the announcement became fodder for gossip, prompting Rahman's legal team to take action against defamatory content. Rahman’s legal team issued a stern warning to those sharing misleading stories about his personal life. The notice demanded the immediate removal of objectionable content within 24 hours. If ignored, legal action under Section 356 of the Bharatiya Nyaya Sanhita, 2023, could follow, with penalties including imprisonment for up to two years. The statement read: “My client informs the hatemongers and sharers of abusive content to remove the objectionable content within the next one hour, with a maximum time duration of 24 hours. Failing this, he will file a criminal defamation case... offenders are liable to be punished with imprisonment of two years, with or without a fine.” Notice to all slanderers from ARR's Legal Team. pic.twitter.com/Nq3Eq6Su2x Rahman’s counsel condemned the spread of “highly imaginary and false stories” about the composer’s private life. The statement highlighted that certain social media platforms and YouTubers were creating baseless content for publicity, harming Rahman’s reputation. It clarified that such actions had no factual basis and were deeply hurtful to his family. The statement further noted that while some social media users claimed insight into Rahman’s marriage, these “perspectives” were baseless and served only to attract attention. On November 19, Rahman shared the news of his separation from Saira Banu in a heartfelt post, expressing the pain of their decision while seeking understanding from friends and fans. He wrote: “We had hoped to reach the grand thirty, but all things, it seems, carry an unseen end. Even the throne of God might tremble at the weight of broken hearts. Yet, in this shattering, we seek meaning, though the pieces may not find their place again. To our friends, thank you for your kindness and for respecting our privacy as we walk through this fragile chapter.” Rahman and Saira Banu share three children—A R Ameen, Khatija and Raheema. Also Read: Bigg Boss 18: Eisha Singh's Brother Clears The Air About Her Relationship With Avinash Mishra In Reality Show: 'She Defines...' Also Read: Bassist Mohini Dey Addresses Rumours Linking Her Divorce To AR Rahman’s Split: 'My Energy Is Not Worth Spending...'None

Gov. Walz presents this year's Minnesota Thanksgiving turkeyPay first, deliver later: Some women are being asked to prepay for their baby

Central Division opponents meet when Predators host the JetsPitt QB Eli Holstein carted off with leg injury

49 Gift Ideas For Anyone Who Still Has A Birthday Before The Year EndsA woman was fatally burnt while she was sleeping on a New York City subway train on December 22. After the incident, the police arrested 33-year-old suspect Sabastian Zapeta-Calil. New York: In a horrifying incident, a woman was fatally burnt while she was sleeping on a New York City subway train on December 22. After the incident, the police arrested 33-year-old suspect Sabastian Zapeta-Calil, who is now facing murder charges. Even as the police is yet to confirm her identity, a post on X has claimed that the victim was Amelia Carter. Since the post went live it garnered over 2.4 million views till now. Soon after the incident, the woman was declared dead. Calil was listed as suspect and was arrested shortly after. Importantly, Zapeta, who is a citizen of Guatemala, entered the the US in 2018 illegally. However he was deported by the Trump administration. It is also being probed on how tha ccused managed to re-enter the country. He has been charged with first and second degree murder . Who is Amelia Carter? “This is Amelia Carter,” A post on X that misidentified the victim. The post while more photos of a woman added, “She was burned alive on the subway yesterday. This is Joe bidens America.” The community note of X. However. clarified, “This is a hoax. This photo is AI. No verified news sources as of 23/12/2024 have given a victim name or statement.” ‘Amelia Carter is a fabricated identity’ “Amelia Carter is a fabricated identity; the photo was generated with artificial intelligence to create a cryptocurrency scam. The police have not disclosed the woman’s identity,” another X community note added An website also published an article on Amelia Carter, which also gave imaginary character a biography. It further added that she was a nurse at Mount Sinai Hospital in New York and also used to worked as an intern on Bernie Sanders’ 2016 presidential campaign, a report by Newsweek said. Click for more latest World news . Also get top headlines and latest news from India and around the world at News9. Subhajit Sankar Dasgupta has nearly 18 years of experience. Currently, he is serving as Associate Editor with news9live.com, a part of Associated Broadcasting Company Pvt Ltd. He started his career with The Pioneer and went on to work in a number of media organisations, including IANS, Financial Express Online, The Political and Business Daily, among others. Apart from online media, he has also worked in print media. Among the beats he covers include politics, sports and infrastructure. He has a Master’s degree in Mass Communication from Guru Jambeshwar University. During his free time, he likes to read books and play table tennis.

To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0.14) No dose-limiting toxicities observed and infusions of TSC-100 and TSC-101 were well-tolerated across all three dose levels Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., on Tuesday, December 10, 2024, at 8:00 a.m. ET WALTHAM, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that updated results from the ongoing ALLOHATM Phase 1 trial of TSC-100 and TSC-101 will be presented during an oral session at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition. TSC-100 and TSC-101 are designed to treat residual disease and prevent relapse in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT) with reduced intensity conditioning. "Disease relapse is the leading cause of death in patients undergoing transplant following reduced intensity conditioning and represents a significant unmet medical need,” said Chrystal U. Louis, M.D., Chief Medical Officer. "As the majority of patients enrolled in both the treatment and control arms were considered at very high risk for relapse, we are highly encouraged by the preliminary ALLOHA study results, which suggest that TSC-100 and TSC-101 have the potential to eliminate residual disease and prevent relapse in patients with AML, ALL, or MDS post-HCT.” "We are very excited by these data and, based on these results, we intend to launch a pivotal trial in the second half of 2025,” said Gavin MacBeath, Ph.D., Chief Executive Officer. "Following recent feedback from the FDA, we believe we have a clear development path and will share our plans at our KOL event tomorrow morning.” In the ongoing ALLOHA Phase 1 trial ( NCT05473910 ), patients receive either TSC-100 or TSC-101 post-HCT, whereas control-arm patients receive HCT alone as per standard of care. To date, 38 patients have been enrolled in the trial and undergone HCT, with 26 in the treatment arm and 12 in the control arm. The key endpoints in the trial are safety and efficacy, with exploratory endpoints including donor chimerism and minimal residual disease (MRD) status. Key Presentation Highlights: Virtual Key Opinion Leader (KOL) Event The Company will host a virtual KOL event featuring Ran Reshef, M.D., M.Sc., on Tuesday, December 10, 2024, at 8:00 a.m. ET to discuss the data presented at ASH, updates with regards to a potential registrational path for the program following its initial meeting with the U.S. Food and Drug Administration, as well as future plans to expand the program, in addition to an update on the Company's PLEXI-TTM Phase 1 solid tumor trial. Dr. Reshef is the Professor of Medicine and Director of the Cellular Immunotherapy Program at Columbia University Irving Medical Center. Details for attending the event can be found here . About TScan Therapeutics, Inc. TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA TM Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company's repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers (the PLEXI-T TM Phase 1 solid tumor trial). The Company is currently enrolling patients into both clinical programs. Forward-Looking Statements This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding the Company's plans, progress, and timing relating to the Company's hematologic malignancies program, including clinical updates of the ALLOHA Phase 1 heme trial, presentation of data, opening of expansion cohorts, and initiation of registrational trials; the Company's plans, progress, and timing relating to the Company's solid tumor program, including, screening, enrolling, and dosing patients, presentation of data, and submission of additional INDs to expand the ImmunoBank; the progress of the hematologic malignancies and solid tumor programs being indicative or predictive of the success of each program; the engagement of CDMO being indicative of successful initiation or support of manufacturing activities or execution of definitive agreements; the Company's current and future research and development plans or expectations; the structure, timing and success of the Company's planned preclinical development, submission of INDs, and clinical trials; the potential benefits of any of the Company's proprietary platforms, multiplexing, or current or future product candidates in treating patients; the Company's ability to fund its operating plan with its existing cash, cash equivalents, and marketable securities; and the Company's goals, strategy and anticipated financial performance. TScan intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, "may,” "might,” "will,” "objective,” "intend,” "should,” "could,” "can,” "would,” "expect,” "believe,” "anticipate,” "project,” "target,” "design,” "estimate,” "predict,” "potential,” "plan,” "on track,” or similar expressions or the negative of those terms. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. The express or implied forward-looking statements included in this release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: the beneficial characteristics, safety, efficacy, therapeutic effects and potential advantages of TScan's TCR-T therapy candidates; TScan's expectations regarding its preclinical studies being predictive of clinical trial results; TScan's recently approved INDs being indicative or predictive of bringing TScan closer to its goal of providing customized TCR-T therapies to treat patients with cancer; the timing of the launch, initiation, progress, expected results and announcements of TScan's preclinical studies, clinical trials and its research and development programs; TScan's ability to enroll patients for its clinical trials within its expected timeline; TScan's plans relating to developing and commercializing its TCR-T therapy candidates, if approved, including sales strategy; estimates of the size of the addressable market for TScan's TCR-T therapy candidates; TScan's manufacturing capabilities and the scalable nature of its manufacturing process; TScan's estimates regarding expenses, future milestone payments and revenue, capital requirements and needs for additional financing; TScan's expectations regarding competition; TScan's anticipated growth strategies; TScan's ability to attract or retain key personnel; TScan's ability to establish and maintain development partnerships and collaborations; TScan's expectations regarding federal, state and foreign regulatory requirements; TScan's ability to obtain and maintain intellectual property protection for its proprietary platform technology and our product candidates; the sufficiency of TScan's existing capital resources to fund its future operating expenses and capital expenditure requirements; and other factors that are described in the "Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations” sections of TScan's most recent Annual Report on Form 10-K and any other filings that TScan has made or may make with the SEC in the future. Any forward-looking statements contained in this release represent TScan's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, TScan explicitly disclaims any obligation to update any forward-looking statements. Contacts Heather Savelle TScan Therapeutics, Inc. VP, Investor Relations 857-399-9840 [email protected] Maghan Meyers Argot Partners 212-600-1902 [email protected]Mayo Clinic Q and A: Exercise tips for heart health

Tuch's short-handed goal helps the Sabres rally for a 4-2 win over the SharksUCF, LSU face off with improved focus in mind

Ananya Panday Says Rumours About Cheating, Fake Academic Qualifications Upset Her: 'People Believed It'Man accused of lighting NYC subway rider on fire told cops he 'drinks a lot,' prosecutor saysWINDSOR, Conn. , Dec. 9, 2024 /PRNewswire/ -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced an initial agreement with Insignia Financial (Insignia) to deliver superannuation member administration services. Insignia Financial supports around 1.1 million superannuation fund members through its wealth management offerings. Upon signing a final binding agreement, more than 1,000 team members in seven offices across Australia will transfer from Insignia to SS&C. The team will then leverage SS&C's in-house technology to automate processes and streamline operations while providing top-notch service delivery to Insignia's customers alongside SS&C's experts. "As a leading global provider of retirement solutions, SS&C is a trusted partner with extensive expertise in fund administration. We anticipate the collaboration with SS&C will provide our more than 1.1 million members with an improved experience delivered by contemporary technology, our people with the opportunity to be part of a large global enterprise, and greater cost efficiencies," said Insignia Financial's CEO Scott Hartley . "We look forward to welcoming Insignia Financial staff to the team and working closely with our new colleagues," said Bill Stone , Chairman and CEO. "Insignia Financial is one of the largest wealth management businesses in Australia and will be our largest client in Australia . This collaboration will put SS&C one step closer to becoming the leading superannuation administration provider in the region. As more funds look to partner with trusted external providers, we look forward to delivering the best technology and service to optimize superannuation administration for Australia's investors." About Insignia Financial Ltd. With origins dating back to 1846, today the Insignia Financial is a leading Australian wealth manager. Insignia Financial provides financial advice, superannuation, wrap platforms and asset management services to members, financial advisers and corporate employers. Further information about Insignia Financial can be found at www.insigniafinancial.com.au About SS&C SS&C is a global provider of services and software for the financial services and healthcare industries. Founded in 1986, SS&C is headquartered in Windsor, Connecticut , and has offices around the world. Some 20,000 financial services and healthcare organizations, from the world's largest companies to small and mid-market firms, rely on SS&C for expertise, scale and technology. Additional information about SS&C (Nasdaq: SSNC) is available at www.ssctech.com . Follow SS&C on Twitter , LinkedIn and Facebook . View original content to download multimedia: https://www.prnewswire.com/news-releases/ssc-signs-agreement-with-insignia-financial-302326720.html SOURCE SS&C

Illumina ILMN has outperformed the market over the past 20 years by 10.11% on an annualized basis producing an average annual return of 18.44%. Currently, Illumina has a market capitalization of $21.57 billion. Buying $100 In ILMN: If an investor had bought $100 of ILMN stock 20 years ago, it would be worth $2,976.69 today based on a price of $135.99 for ILMN at the time of writing. Illumina's Performance Over Last 20 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by an editor. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Saturn Oil & Gas: Strong Buy On Improving Fundamentals And Balance Sheet Repair

They were all exceptional – Mikel Arteta loved seeing Arsenal run riot in Lisbon

Pathstone Holdings LLC grew its holdings in shares of iShares 7-10 Year Treasury Bond ETF ( NASDAQ:IEF – Free Report ) by 581.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 50,898 shares of the exchange traded fund’s stock after acquiring an additional 43,425 shares during the period. Pathstone Holdings LLC’s holdings in iShares 7-10 Year Treasury Bond ETF were worth $4,994,000 as of its most recent SEC filing. A number of other hedge funds also recently modified their holdings of the business. Capital Investment Counsel Inc bought a new stake in shares of iShares 7-10 Year Treasury Bond ETF in the 2nd quarter valued at $25,000. Innealta Capital LLC bought a new stake in iShares 7-10 Year Treasury Bond ETF during the second quarter valued at $28,000. Hazlett Burt & Watson Inc. acquired a new stake in iShares 7-10 Year Treasury Bond ETF during the 3rd quarter worth about $34,000. Van ECK Associates Corp bought a new position in shares of iShares 7-10 Year Treasury Bond ETF in the 3rd quarter worth about $35,000. Finally, Riggs Asset Managment Co. Inc. acquired a new position in shares of iShares 7-10 Year Treasury Bond ETF in the 2nd quarter valued at about $36,000. Institutional investors and hedge funds own 81.48% of the company’s stock. iShares 7-10 Year Treasury Bond ETF Stock Performance Shares of IEF stock opened at $93.60 on Friday. iShares 7-10 Year Treasury Bond ETF has a fifty-two week low of $91.02 and a fifty-two week high of $99.18. The stock has a 50 day simple moving average of $95.81 and a two-hundred day simple moving average of $95.29. The company has a market cap of $33.25 billion, a P/E ratio of -21.67 and a beta of 0.05. iShares 7-10 Year Treasury Bond ETF Increases Dividend iShares 7-10 Year Treasury Bond ETF Company Profile ( Free Report ) iShares 7-10 Year Treasury Bond ETF (the Fund) is an is an exchange-traded fund. The Fund seeks to track the investment results of an index composed of the United States Treasury bonds with remaining maturities between seven and ten years. The Fund seeks to track the investment results of the Barclays U.S. See Also Want to see what other hedge funds are holding IEF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares 7-10 Year Treasury Bond ETF ( NASDAQ:IEF – Free Report ). Receive News & Ratings for iShares 7-10 Year Treasury Bond ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares 7-10 Year Treasury Bond ETF and related companies with MarketBeat.com's FREE daily email newsletter .

EMERYVILLE, Calif. , Nov. 26, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 2:35 p.m. ET . The presentation will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations . About Dynavax Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visit www.dynavax.com . For Investors/Media: Paul Cox pcox@dynavax.com 510-665-0499 Nicole Arndt narndt@dynavax.com 510-665-7264 View original content to download multimedia: https://www.prnewswire.com/news-releases/dynavax-to-present-at-the-7th-annual-evercore-healthconx-conference-302315117.html SOURCE Dynavax TechnologiesU.S. stock indexes edged higher in morning trading Tuesday, as gains for some Big Tech stocks made up for weakness elsewhere in the market. The S&P 500 rose 0.4%. The Dow Jones Industrial Average was up 14 points, or 0.1%, as of 9:58 a.m. Eastern time. The tech-heavy Nasdaq composite was up 0.7%. Gains in technology, financial and other sectors tempered a pullback by health care, energy and other stocks. Chip company Broadcom rose 1.3%, while semiconductor giant Nvidia, whose enormous valuation gives it an outsize influence on indexes, rose 1.2%. American Airlines fell 1.2% after the airline briefly grounded flights nationwide due to a technical issue. U.S. Steel slipped 0.5% a day after an influential government panel failed to reach consensus on the possible national security risks of the nearly $15 billion proposed sale to Nippon Steel of Japan. Treasury yields rose in the bond market. The yield on the 10-year Treasury rose to 4.62% from 4.59% late Monday. European markets were mostly higher. Markets in Asia mostly gained ground. U.S. markets will close at 1 p.m. Eastern and stay closed Wednesday for Christmas. Wall Street has several economic reports to look forward to this week, including a weekly update on unemployment benefits on Thursday.

B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of Builders FirstSource, Inc. ( NYSE:BLDR – Free Report ) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 7,135 shares of the company’s stock, valued at approximately $1,383,000. Other hedge funds have also recently modified their holdings of the company. Innealta Capital LLC acquired a new position in Builders FirstSource in the 2nd quarter valued at about $27,000. Armstrong Advisory Group Inc. purchased a new stake in Builders FirstSource during the 3rd quarter worth approximately $30,000. First Horizon Advisors Inc. lifted its holdings in Builders FirstSource by 42.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 253 shares of the company’s stock worth $35,000 after buying an additional 75 shares in the last quarter. New Millennium Group LLC purchased a new position in Builders FirstSource in the 2nd quarter valued at approximately $38,000. Finally, Reston Wealth Management LLC purchased a new stake in shares of Builders FirstSource during the third quarter worth $39,000. Hedge funds and other institutional investors own 95.53% of the company’s stock. Wall Street Analyst Weigh In BLDR has been the subject of a number of recent research reports. Wedbush reiterated an “outperform” rating and issued a $230.00 target price on shares of Builders FirstSource in a report on Wednesday, November 6th. Jefferies Financial Group upped their target price on shares of Builders FirstSource from $185.00 to $223.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Benchmark reduced their target price on shares of Builders FirstSource from $220.00 to $200.00 and set a “buy” rating on the stock in a report on Wednesday, August 7th. Bank of America boosted their price target on shares of Builders FirstSource from $165.00 to $198.00 and gave the stock a “neutral” rating in a report on Thursday, September 19th. Finally, Stifel Nicolaus lowered their target price on shares of Builders FirstSource from $217.00 to $195.00 and set a “buy” rating for the company in a research note on Thursday, August 8th. Five research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Builders FirstSource has an average rating of “Moderate Buy” and a consensus target price of $206.47. Builders FirstSource Price Performance BLDR stock opened at $178.52 on Friday. The business has a 50 day simple moving average of $186.33 and a 200-day simple moving average of $167.97. The company has a market capitalization of $20.54 billion, a P/E ratio of 17.43, a PEG ratio of 1.00 and a beta of 2.08. Builders FirstSource, Inc. has a twelve month low of $130.75 and a twelve month high of $214.70. The company has a current ratio of 1.77, a quick ratio of 1.16 and a debt-to-equity ratio of 0.83. Builders FirstSource ( NYSE:BLDR – Get Free Report ) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $3.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.09 by ($0.02). Builders FirstSource had a return on equity of 33.55% and a net margin of 7.40%. The business had revenue of $4.23 billion for the quarter, compared to analysts’ expectations of $4.44 billion. During the same period in the previous year, the business posted $4.24 earnings per share. The company’s revenue for the quarter was down 6.7% on a year-over-year basis. As a group, equities analysts anticipate that Builders FirstSource, Inc. will post 11.56 EPS for the current year. Builders FirstSource announced that its Board of Directors has authorized a stock buyback plan on Tuesday, August 6th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the company to buy up to 5.3% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued. Insider Activity at Builders FirstSource In related news, Director Cleveland A. Christophe sold 10,000 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $178.41, for a total transaction of $1,784,100.00. Following the completion of the sale, the director now directly owns 33,083 shares of the company’s stock, valued at $5,902,338.03. This trade represents a 23.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link . 1.80% of the stock is currently owned by insiders. About Builders FirstSource ( Free Report ) Builders FirstSource, Inc, together with its subsidiaries, manufactures and supplies building materials, manufactured components, and construction services to professional homebuilders, sub-contractors, remodelers, and consumers in the United States. It offers lumber and lumber sheet goods comprising dimensional lumber, plywood, and oriented strand board products that are used in on-site house framing; manufactured products, such as wood floor and roof trusses, floor trusses, wall panels, stairs, and engineered wood products; and windows, and interior and exterior door units, as well as interior trims and custom products comprising intricate mouldings, stair parts, and columns under the Synboard brand name. Featured Stories Receive News & Ratings for Builders FirstSource Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Builders FirstSource and related companies with MarketBeat.com's FREE daily email newsletter .Music industry in mourning as icon passes away suddenly aged 64